Atopic Dermatitis

The AJMC® Atopic Dermatitis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin condition that typically develops in early childhood.

Latest News

Roflumilast cream | Image Credit: © luchschenF-stock.adobe.com
Roflumilast Cream 0.05% Durable, Safe for Younger Pediatric Patients

August 15th 2025

The INTEGUMENT-OLE study is an open-label extension analysis that followed a primary investigation from the phase 3 INTEGUMENT-PED trial, which investigated the efficacy and safety of once-daily roflumilast cream 0.05% for atopic dermatitis in children aged 2 to 5 years.

atopic dermatitis | Image Credit: © wladimir1804-stock.adobe.com
Long-Term Lebrikizumab Provides Sustained Skin Clearance in Atopic Dermatitis

August 5th 2025

FDA approval | Image Credit: Maggie-sora.chatgpt.com
FDA Approves Delgocitinib for Moderate to Severe Hand Eczema

July 24th 2025

Atopic Dermatitis | Image Credit: Veranika-stock.adobe.com
Dupilumab Shows Strong Efficacy in SCORAD-Based AD Assessment

July 14th 2025

Atopic dermatitis | Image Credit: © slobodyan_78-stock.adobe.com
Rezpegaldesleukin Potentially Promising for Atopic Dermatitis

July 8th 2025

Topical Therapies for the Treatment of Atopic Dermatitis: Balancing Safety, Efficacy, and Access

Develop a deeper understanding of the atopic dermatitis (AD) patient journey, explore topical therapies and treatment sequencing advancements, and gain insight regarding the payer’s perspective on AD therapies.

Atopic Dermatitis Payer Perspectives

More News

graphic of patients and doctors
July 17th 2021

Increased Mortality Seen Among Patients With Concomitant AD, Asthma

Gianna Melillo
Researchers assess mortality rates among those with just asthma, just atopic dermatitis, and individuals with both conditions in Denmark.
evaluating dupilumab in a value based health plan
May 10th 2021

Evaluating Dupilumab for Placement in a Value-Based Health Plan

Larry Hanover
Dupilumab is effective for atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps, but a recent presentation noted the payer challenge in placing the biologic in an optimal tier.
Retrospective Study Examines Dupilumab Performance in Asian Youth Population
April 17th 2021

Retrospective Study Examines Dupilumab Performance in Asian Youth Population

AJMC Staff
Patients had atopic dermatitis for nearly 10 years before starting the biologic therapy.
Mother and child discussing chart with doctor
April 9th 2021

Maternal History of Asthma Drives Risk of Atopic Dermatitis for Their Children

Jaime Rosenberg
Children who were born to women with a history of asthma had a 45% increased risk of being diagnosed with atopic dermatitis/eczema up to age 8 years.
Dermatologist examining patient
March 31st 2021

Patient Evaluation Scarce Among Dermatologists in France Treating Atopic Dermatitis

Larry Hanover
A survey in France found that systemic medications are used by only half of dermatologists in treating atopic dermatitis, with methotrexate used more than cyclosporine.
Doctor examining patient with eczema
March 27th 2021

No Link Found Between Nutrition, Risk of Atopic Dermatitis in Children

Larry Hanover
There is no consistent evidence showing clear benefit of various nutritional factors on the risk of atopic dermatitis.
Even With Mild Disease, Children With Atopic Dermatitis Have Comorbidities
March 5th 2021

Even With Mild Disease, Children With Atopic Dermatitis Have Comorbidities

Allison Inserro
Despite the level of disease severity of atopic dermatitis, children with the condition usually have at least 1 other inflammatory or atopic comorbidity, according to new study results.
Dr Matthew J. Zirwas Discusses Step Therapy in Patients With Atopic Dermatitis
February 12th 2021

Dr Matthew J. Zirwas Discusses Step Therapy in Patients With Atopic Dermatitis

Ohio dermatologist Matthew J. Zirwas, MD, offers his view on what step therapy would look like in patients with atopic dermatitis.
Man with neck eczema
February 4th 2021

Dupilumab Is Safe, Effective Among Elderly Patients With AD

Larry Hanover
A new study of dupilumab indicates that the drug is a safe and effective treatment for atopic dermatitis (AD) in elderly patients, with efficacy comparable to that seen in younger patients.
Dr Matthew J. Zirwas on Communicating About AD Treatment Persistence
January 10th 2021

Dr Matthew J. Zirwas on Communicating About AD Treatment Persistence

Patients often ask how long they have to stay on biologic treatment for atopic dermatitis (AD), but there is a risk if therapy is stopped, says Matthew J. Zirwas, MD, a dermatologist in Ohio.
<1
...
45678

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo